Over the past decade, mounting clinical evidence has shown that social determinants of health (SDOH) – defined by the World Health Organization (WHO) as “the conditions in which people are born, grow, live, work and age”— are equally, if not more, important to driving health outcomes than a patient’s genes.
Amy Valley, PharmD, Vice President of Clinical Strategy and Technology Solutions for VitalSource™ GPO, sat down with John Frownfelter, MD, FACP, Chief Medical Officer for Jvion, to discuss how practices can leverage artificial intelligence (AI) to identify and address social determinants of health. Using AI tools, practices can not only take advantage of automation and data analytics to more easily identify patients that may be impacted by social determinants, they can also determine which patients have risk factors that may require intervention.
“Knowing something is true about the patient is the first step,” says Dr. Frownfelter. “The insights these tools can provide bring focus to not only which patients are at risk, but the particular reasons why… helping oncologists focus differently. It isn’t new medicine, but rather what am I going to do for this patient that I wasn’t thinking of doing before.”
Watch the rest of their conversation, which features more insights on why social determinants are particularly important in oncology care, steps practices can take to curb their effects and how practices can justify the value of addressing social determinants in lowering the overall cost of care and improving outcomes, here.